The Xue Lab is a translational research group investigating the mechanisms of retinal inflammation and degeneration in the context of age-related macular degeneration (AMD), uveitis and retinal gene therapy. Our aim is to translate improved understanding of disease mechanisms into clinical trials for patients with retinal diseases, and ultimately new therapies to prevent sight loss.
Age-related macular degeneration (AMD) is the leading cause of sight loss affecting one in eight individuals over the age of 60, yet there is currently no treatment for the majority of macular degeneration. Uveitis is another major cause of severe visual impairment in the working age. Current therapy involves systemic immunosuppression which is associated with potentially severe adverse effects and loss of quality of life. Retinal inflammation and immunity play key roles in the pathogenesis of both conditions. In addition, retinal inflammation is a major limiting factor on the clinical efficacy of gene therapies for inherited retinal diseases.
- Investigate the mechanisms of retinal inflammation and degeneration using disease models
- Develop new treatments to control intraocular inflammation and prevent sight loss from age-related macular degeneration and uveitis
- Improve the safety and efficacy of retinal surgery and gene therapy
- Translate laboratory and pre-clinical findings into clinical trials
Clinical Ophthalmology Research Group
Calliope Dendrou, Wellcome Centre for Human Genetics
Laurel Chandler, DPhil (Merton College Oxford)
Ayesha Musa, FHS student 2020 (Jesus College Oxford)
James Aylward, BM-BCh (St Hilda's College Oxford)
Dun Jack Fu, BM-BCh PhD (St Hugh's College Oxford)
Olivia Parham, FHS student 2016 (New College Oxford)
Howell Fu, FHS student 2015 (Exeter College Oxford)